Bronchiolitis obliterans (BO) is a rare but serious complication of paediatric allogenic bone marrow transplantation (BMT). Currently, there is no clear evidence that therapeutic interventions have a positive impact on the course of the disease. We here report our experience with high-dose pulse methylprednisolone therapy in children after BMT. Nine patients fulfilling clinical and radiologic signs of BO were included in this analysis. The total amount of treatment cycles with pulse methylprednisolone therapy ranged from 1 to 6 cycles (median four cycles). Oxygen saturation increased significantly with normalization of oxygen saturation at the end of therapy in all individuals. Normal oxygen saturation was maintained in all but one patient during follow-up (mean follow-up period 42 {plus/minus} 20 months, range 19-67 months). Forced expiratory volume in 1 s (FEV1) was within the normal range prior BMT and significantly diminished at the time of BO diagnosis. Treatment led to stabilization of lung function, with a significant improvement of FEV1 after 2 months. In all, 7/9 patients remained in clinically stable condition without further deterioration of lung function during follow-up. These data would suggest that anti-inflammatory therapy may be a valuable treatment option in paediatric patients with bronchiolitis obliterans after BMT. Bone Marrow Transplantation (2005) 36, 135-138.
matory treatment
Both infectious and noninfectious pulmonary complications are frequently encountered in paediatric patients undergoing bone marrow transplantation (BMT).
1-4 Noninfectious manifestations can be subdivided into different entities that include idiopathic pneumonia, pulmonary fibrosis and bronchiolitis obliterans (BO). [4] [5] [6] BO post-BMT is characterized by the development of fixed airway obstruction in the absence of airway infection. [6] [7] [8] [9] The onset of BO is insidious and clinical symptoms are frequently misinterpreted; the disease is therefore often diagnosed at a relatively late stage. The immunologic mechanisms of BO remain poorly understood, but histopathologic studies have demonstrated an initial inflammatory response of terminal and respiratory bronchioli that ultimately leads to scarring and total occlusion of the conducting airways. 10, 11 There is currently insufficient evidence that the progressive damage of the BO can be changed by treatment. Many patients receive immunosuppressive therapy, but there is a lack of controlled trials in both paediatric and adult patients. Conceptually, anti-inflammatory therapy may be successful, if initiated at an early stage, that is, before permanent damage and scarring has occurred. We here report our experience with a protocol of high-dose pulse methylprednisolone therapy in paediatric patients with BO post-BMT, which suggests that high-dose methylprednisolone therapy may halt the progression of lung disease.
Methods
The study population consisted of nine patients aged 1-17 years (mean age7s.d.: 8.875.6 years) from the BMT centre at the University of Essen. Baseline characteristics of the study population are shown in Table 1 . The diagnosis of BO was based on the presence of irreversible airway obstruction in the absence of infection, as proposed by the International Society for Heart and Lung transplantation. 12 These criteria were modified to include the following five criteria: (1) airway obstruction7hypoxaemia not normalizing after b-2 agonist treatment, [13] [14] [15] (2) absence of pulmonary infiltrates, (3) absence of infectious organisms in blood and respiratory secretion7bronchoal-veolar lavage, (4) reduction in FEV 1 in the absence of airway restriction (in patients cooperating in pulmonary function measurements), 14, 15 (5) bronchial dilatation and mosaic pattern of attenuation on high-resolution CT scan. [16] [17] [18] Patients fulfilling at least four of five criteria were diagnosed as BO and treated with high-dose pulse corticosteroid therapy (methylprednisolone 10 mg/kg body weight/day) for 3 days. Courses of pulse therapy were repeated on a monthly basis in patients with continuous symptoms up to a maximum of six cycles. In addition to systemic corticosteroid therapy, patients received inhaled budesonide (2 Â 400 mg/day) for the duration of systemic corticosteroids therapy.
Statistical analysis
Data were tested for normal distribution by KolmogorovSmirnov test and expressed as mean7standard deviation (s.d.). Comparison were performed with paired t-tests for changes within groups.
Results
The time period between onset of symptoms and diagnosis of BO ranged between 4 and 205 days (mean7s.d.: 56780 days). Clinical findings at presentation are summarized in Table 2 . One patient had acute GvHD and five patients chronic GvHD at the time of presentation. 19 All patients had dyspnoea and either prolonged expiratory phase or wheezing, and all but one patient were afebrile at the time of presentation. Respiratory rate was above the predicted normal range in 6/9 children (Table 1) . 20 None of the patients had any pulmonary infiltrates on chest X-ray. Bronchoalveolar lavage (BAL) to exclude infection was performed in seven of nine patients (including the patient with fever). Baseline oxygen saturation on room air was below 95% in 6/9 patients (Table 1) .
The total amount of treatment cycles with pulse methylprednisolone therapy ranged from 1 to 6 months (median 4 months). Oxygen saturation at baseline and after pulse corticosteroid therapy is shown in Figure 1 . There was a significant increase in oxygen saturation after treatment, with normalization of oxygen saturation at the end of therapy in all individuals (Po0.02, paired t-test). Normal oxygen saturation was maintained in all but one patient during follow-up (mean follow-up period 42720 months, range 19-67 months).
Lung function measurements were available for 5/9 patients (all patients who were able to cooperate with pulmonary function measurements). Forced expiratory volume in one second (FEV 1 ) was within the normal range prior to BMT and significantly diminished at the time of BO diagnosis (Figure 2) . Treatment lead to stabilization of lung function, with a significant improvement of FEV 1 after 2 months (Po0.03; paired t-test). This improvement in lung function was maintained during follow-up (Figure 2 ), but normalization of pulmonary function was not achieved. FVC followed a similar pattern, but changes did not reach statistical significance (data not shown).
In all, 7/9 patients remained in clinically stable condition without further deterioration of lung function during follow-up. One patient (patient 9), who had the most severe manifestation at baseline, died despite treatment of respiratory failure 7 months after diagnosis. Another patient (patient 5) developed progression of symptoms and deterioration of lung function 1 year after pulse steroid Treatment of bronchiolitis obliterans F Ratjen et al therapy. He was treated with azithromycin, which led to improvement in both symptoms and lung function.
Discussion
We here report our experience with high-dose methylprednisolone treatment for BO in patients after BMT. Lung function and oxygen saturation improved with treatment and resulted in stabilization of the clinical status in the majority of patients. These data would suggest that antiinflammatory therapy may be a valuable treatment option in paediatric patients with BO after BMT.
The present study has a number of limitations. First, it did not include a control group and we can therefore not definitely prove that treatment altered the natural course of the disease. However, most observational studies would indicate that BO has a relative poor prognosis and that progression of lung function impairment is seen in the majority of patients. [6] [7] [8] [9] 21 Secondly, since biopsies were not performed in these children, we cannot confirm absolutely the diagnosis of BO. Based on this suggestive clinical scenarion, we can state that paediatric patients with this cluster of symptoms have a high rate of response to pulse steroid therapy. Thirdly, lung function parameters were only available in a fraction of the population. This is related to the inability of patients o6 years of age to cooperate with standard pulmonary function tests. However, pulmonary function data are supported by the results of oxygen saturation which normalized in all patients after corticosteroid treatment. Thirdly, the cohort was relatively small, which reflects the low frequency of this complication in paediatric patients after BMT. A multi-centre approach would be needed to sample a larger patient cohort. Finally, we have no convincing evidence that pulse methylprednisolone therapy is the ideal intervention for paediatric patients with BO after BMT and other treatment options such as oral prednisone or cyclophosphamide may be equally effective. We have chosen this form of therapy, since it has been shown to be effective in other inflammatory lung diseases such as interstitial lung diseases. 22 The observation in one patient who deteriorated 1 year after cessation of pulse therapy and was successfully treated with azithromycin would suggest that macrolide therapy may also be an option for this patient population. Azithromycin and other macrolides have been shown to improve survival in patients with diffuse panbronchiolitis, 23 and recent evidence suggest that it may also be effective in BO after lung transplantation. 24, 25 The mechanism of action is unclear, but may include downregulation of pro-inflammatory cytokines such as TNF alpha by macrolides. 26 While it is presently unclear which form of intervention should be preferred, this report can be viewed as a proof of concept that therapeutic agents suppressing the inflammatory process may be beneficial in paediatric patients with BO after BMT.
Many of the pulmonary complications arising after BMT have a rather dramatic onset. This is particularly true for infectious complications which are usually associated with fever and/or prominent cough. In contrast, BO is a more insidious disease which develops slowly without causing major symptoms. The limitations in exercise capacity are often not appreciated in a patient population which in general is not very active physically. Close observation of these patients is therefore imperative to allow for an early diagnosis of the disease process. In patients receiving lung transplantation, daily spirometry with portable devices has become routine and reproducible deterioration in FEV 1 is considered to be a valid parameter to detect signs of pulmonary complications such as rejection, infection or BO. 27 Our study population showed marked deterioration of lung function at the time of diagnosis and, retrospectively, symptoms were present long before clinical diagnosis in the majority of patients. The observation in one patient, in whom treatment was initiated within 4 days after onset of symptoms and who had the least pronounced deterioration in lung function, would also support this concept. Therefore, similar surveillance measures as in lung transplantation may be useful to avoid permanent loss in lung function and to allow for an earlier and possibly more effective intervention.
In conclusion, our results suggest that pulse methylprednisolone therapy appears to be effective in holding the progression of lung disease in paediatric patients with BO following BMT. Further studies should compare different treatment modalities as well as the effect of earlier intervention to avoid permanent damage to the lung in this patient population. Treatment of bronchiolitis obliterans F Ratjen et al
